Pacira BioSciences

Q2 FY2026 EarningsQ2 FY26 results beat consensus on both top and bottom lines: revenue of $192.4M exceeded the $191.0M expected, and normalized EPS of $0.73 beat the $0.65 forecast. Growth was driven by the core product EXPAREL, which grew 3% YoY to $147.8M, alongside a 22% surge in iovera° sales. Management updated FY26 revenue guidance to $735M–$760M to account for the iovera° divestiture to Zimmer Biomet, while reiterating strong EXPAREL sales targets of $600M–$620M.